Biochemometric Analysis of Fatty Acid Amide Hydrolase Inhibition by Echinacea Root Extracts

Abstract

Recent research demonstrates that Echinacea possesses cannabimimetic activity with potential applications beyond common contemporary uses for relief of cold and flu symptoms. In this study, we investigated the in vitro inhibitory effect of root extracts of Echinacea purpurea and Echinacea angustifolia on fatty acid amide hydrolase, the main enzyme that degrades the endocannabinoid anandamide. The objective was to relate variation in bioactivity between commercial Echinacea genotypes to their phytochemical profiles and to identify determinants of activity using biochemometric analysis. Forty root extracts of each of species were tested for inhibition of fatty acid amide hydrolase and analyzed by HPLC-DAD/MS to identify and quantitate alkylamides and caffeic acid derivatives. Fatty acid amide hydrolase inhibition ranged from 34 – 80% among E. angustifolia genotypes and from 33 – 87% among E. purpurea genotypes. Simple linear regression revealed the caffeic acid derivatives caftaric acid and cichoric acid, and the alkylamide dodeca-2E,4Z-diene-8,10-diynioc acid 2-methylbutylamide, as the strongest determinants of inhibition in E. purpurea (r* = 0.53, 0.45, and 0.20, respectively) while in E. angustifolia, only CADs were significantly associated with activity, most notably echinacoside (r* = 0.26). Regression analysis using compound groups generated by hierarchical clustering similarly indicated that caffeic acid derivatives contributed more than alkylamides to in vitro activity. Testing pure compounds identified as determinants of activity revealed cichoric acid (IC₅₀ = 45 ± 4 µM) and dodeca-2E,4E,8Z,10E-tetraenoic acid isobutylamide (IC₅₀ = 54 ± 2 µM) as the most active. The results suggest that several phytochemicals may contribute to Echinaceaʼs cannabimimetic activity and that ample variation in genotypes exists for selection of high-activity germplasm in breeding programs.

Key words

Echinacea - Asteraceae - coneflowers - alkamides - phenolics - endocannabinoid system

Publication History

Received: 30 May 2020

Accepted after revision: 02 October 2020

Article published online:
09 December 2020

• References

• 1 Shemluck M. Medicinal and other uses of the compositae by Indians in the United States and Canada. J Ethnopharmacol 1982; 5: 303-358
• 2 Smith T, Guillespie M, Eckl V, Knepper J, Morton-Reynolds C. US Retail Sales of Herbal Supplements Increase by 9.4 % in 2018. HerbalGram 2018; 123: 62-73
• 3 Blumenthal M, Hall T, Goldberg A, Kunz T, Dinda K. eds. The ABC Guide to clinical Herbs. Austin, Texas: American Botanical Council; 2003: 235-246
• 4 Binns SE, Livesey JF, Arnason JT, Baum BR. Phytochemical variation in echinacea from roots and flowerheads of wild and cultivated populations. J Agric Food Chem 2002; 50: 3673-3687
• 5 Binns SE, Livesey JF, Arnason JT, Baum BR. Phytochemical variation within populations of Echinacea angustifolia (Asteraceae). Biochem Syst Ecol 2002; 30: 837-854
• 6 Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine 2003; 10: 66-86
• 7 Haller J, Hohmann J, Freund TF. The effect of Echinacea preparations in three laboratory tests of anxiety: comparison with chlordiazepoxide. Phytother Res 2010; 24: 1605-1613
• 8 Haller J, Freund TF, Pelczer KG, Füredi J, Krecsak L, Zámbori J. The anxiolytic potential and psychotropic side effects of an Echinacea preparation in laboratory animals and healthy volunteers. Phytother Res 2013; 27: 54-61
• 9 Chicca A, Raduner S, Pellati F, Strompen T, Altmann KH, Schoop R, Gertsch J. Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts. Int Immunopharmacol 2009; 9: 850-858
• 10 Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov 2018; 17: 623-639
• 11 Di Marzo V, Bisogno T, Melck D, Ross R, Brockie H, Stevenson L, Pertwee R, De Petrocellis L. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett 1998; 436: 449-454
• 12 Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008; 153: 319-334
• 13 Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003; 119: 747-757
• 14 Hohmann J, Rédei D, Forgo P, Szabó P, Freund TF, Haller J, Bojnik E, Benyhe S. Alkamides and a neolignan from Echinacea purpurea roots and the interaction of alkamides with G-protein-coupled cannabinoid receptors. Phytochemistry 2011; 72: 1848-1853
• 15 Woelkart K, Xu W, Pei Y, Makriyannis A, Picone RP, Bauer R. The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots. Planta Med 2005; 71: 701-705
• 16 Thors L, Belghiti M, Fowler CJ. Inhibition of fatty acid amide hydrolase by kaempferol and related naturally occurring flavonoids. Br J Pharmacol 2008; 155: 244-252
• 17 Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, Altmann KH, Gertsch J. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem 2006; 281: 14192-14206
• 18 Oboh G, Agunloye OM, Adefegha SA, Akinyemi AJ, Ademiluyi AO. Caffeic and chlorogenic acids inhibit key enzymes linked to type 2 diabetes (in vitro): a comparative study. J Basic Clin Physiol Pharmacol 2015; 26: 165-170
• 19 Chiou SY, Sung JM, Huang PW, Lin SD. Antioxidant, antidiabetic, and antihypertensive properties of Echinacea purpurea flower extract and caffeic acid derivatives using In Vitro models. J Med Food 2017; 20: 171-179
• 20 Rastogi H, Jana S. Evaluation of inhibitory effects of caffeic acid and quercetin on human liver cytochrome p450 activities. Phytother Res 2014; 28: 1873-1878
• 21 Baell JB. Feeling natureʼs PAINS: Natural products, natural product drugs, and Pan Assay Interference Compounds (PAINS). Nat Prod 2016; 79: 616-628
• 22 Woelkart K, Kollroser M, Magnes C, Sinner F, Frye RF, Derendorf H, Bauer R, Butterweck V. Absolute/relative bioavailability and metabolism of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (tetraenes) after intravenous and oral single doses to rats. Planta Med 2011; 77: 1794-1799
• 23 Bel-Rhlid R, Pagé-Zoerkler N, Fumeaux R, Ho-Dac T, Chuat JY, Sauvageat JL, Raab T. Hydrolysis of chicoric and caftaric acids with esterases and Lactobacillus johnsonii in vitro and in a gastrointestinal model. J Agric Food Chem 2012; 60: 9236-9241
• 24 Wang SJ, Zeng J, Yang BK, Zhong YM. Bioavailability of caffeic acid in rats and its absorption properties in the Caco-2 cell model. Pharm Biol 2014; 52: 1150-1157
• 25 Bergeron C, Livesey JF, Awang DV, Arnason JT, Rana J, Baum BR, Letchamo W. A quantitative HPLC method for the quality assurance of Echinacea products on the North American market. Phytochem Anal 2000; 11: 207-215
• 26 Liu R. Pharmacology and Toxiclogy of Echinacea, Souroubea and Platanus spp. [PhD Thesis]. Ottawa: University of Ottawa; 2019: 1-178
• 27 Anderson MJ, Legendre P. An empirical comparison of permutation methods for tests of partial regression coefficients in a linear model. J Stat Comput Sim 1999; 62: 271-303
• 28 Legendre P, Anderson MJ. Distance-based redundancy analysis: testing multispecies responses in multifactorial ecological experiments. Ecol Monogr 1999; 69: 1-24
• 29 Legendre P, Legendre L. Numerical Ecology. 3rd ed.. ed. Amsterdam: Elsevier; 2012
• 30 R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2019. Accessed February 2, 2020 at: https://www.r-project.org/